A new shot called olpasiran can slash a dangerous type of cholesterol called lipoprotein(a) by more than double its starting level in people with heart disease — meaning it doesn’t just lower it, it...

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

Randomized Controlled Trial

Human

2022 Nov 17

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

Score: 66

DOI: 10.1056/nejmoa2211023

Similar Assertions

A new drug called olpasiran can dramatically lower a harmful type of cholesterol called lipoprotein(a) in people with heart disease — at the highest dose, it doesn’t just reduce it, it nearly wipes it out completely compared to a dummy pill.

88%

For people with heart disease and high levels of a fatty protein called lipoprotein(a), a new drug called olpasiran mostly caused only mild reactions at the injection site, like redness or soreness, and was otherwise safe to use.

81%